Sientra to Release First Quarter Financial Results on May 8, 2019
19 April 2019 - 6:15AM
Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company
(“Sientra” or the “Company”), announced today that the Company will
release its first quarter 2019 financial results on Wednesday, May
8, 2019 after market close.
Sientra will hold a conference call on
Wednesday, May 8, 2019 at 4:30 p.m. ET to discuss the results. A
press release disclosing the Company's financial results will be
distributed at approximately 4:00 p.m. ET that same day.
The dial-in numbers are 844-464-3933 for
domestic callers and 765-507-2612 for international callers. The
conference ID is 4982524. A live webcast of the conference call
will be available on the Investor Relations section of the
Company's website at www.sientra.com.
A replay of the call will be available starting
on May 8, 2019 at 7:30 p.m. ET through May 15, 2019 at 11:59 p.m.
ET. To access the replay, dial 855-859-2056 for domestic callers
and 404-537-3406 for international callers and use the replay
conference ID 4982524. The webcast will be available on the
Investor Relations section of the Company’s website for 30 days
following the completion of the call.
About Sientra
Headquartered in Santa Barbara, California,
Sientra is a diversified global medical aesthetics company and a
leading partner to aesthetic physicians. The Company offers a suite
of products designed to make a difference in patients' lives by
enhancing their body image, growing their self-esteem, and
restoring their confidence. Sientra has developed a broad portfolio
of products with technologically differentiated characteristics,
supported by independent laboratory testing and strong clinical
trial outcomes. The Company’s Breast Products Segment includes its
OPUS™ breast implants, the first fifth generation breast implants
approved by the FDA for sale in the United States, its
ground-breaking Allox2® breast tissue expander with patented
dual-port and integral drain technology, and BIOCORNEUM® the #1
performing, preferred and recommended scar gel of plastic
surgeons(*). The Company’s miraDry Segment comprises its miraDry®
system, which is approved for sale in over 40 international
markets, and is the only non-invasive FDA-cleared device for the
permanent reduction of underarm sweat, odor and hair of all
colors.____________________(*) Data on file
Investor Relations:Neil
Bhalodkar805-679-8845
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Apr 2024 to May 2024
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From May 2023 to May 2024